

Recommended guidelines for prophylactic antiemetic treatment before administering ENHERTU (trastuzumab deruxtecan) within licensed indications

Please refer to SmPC for more information on licensed indications



ENHERTU has a conditional marketing authorisation.¹ This means that further evidence on this medicinal product is awaited
Prescribing information and the adverse event reporting statement can be accessed from the bottom of page



ENHERTU is highly emetogenic, which includes delayed nausea and/or vomiting¹

SmPC¹

Recommends a **2- or 3-drug prophylactic regimen** including a combination of the following medicinal products:

- Dexamethasone
- +/- NK₁ RA
- 5-HT₃ RA

MASCC-ESMO guidelines 2024²

Recommends a **3-drug prophylactic regimen*** including a combination of the following medicinal products:

- Dexamethasone
- NK₁ RA
- 5-HT₃ RA

NCCN[®] guidelines 2025³

Recommends a **4-drug prophylactic regimen¹** including a combination of the following medicinal products:

- Dexamethasone
- NK₁ RA
- 5-HT₃ RA
- Olanzapine**

Please refer to the respective SmPCs for more information on licensed indications

*Recommendation for carboplatin AUC ≥5 to which ENHERTU appears to have a similar emetogenic potential. ¹Recommendation for high emetic risk parenteral anticancer agents, which includes ENHERTU.

Using an appropriate upfront antiemetic regimen from the first cycle may help to reduce the need for dose reductions of ENHERTU⁴

Please refer to the **ENHERTU SmPC for the full list of adverse events.**¹

Examples of NK₁ RAs include aprepitant, fosaprepitant, fosnetupitant, netupitant and rolapitant.

****Olanzapine is not licensed for use in the management of chemotherapy-induced nausea and vomiting.**

Abbreviations: 5-HT₃, serotonin type 3; AUC, area under the curve; ESMO, European Society for Medical Oncology; MASCC, Multinational Association of Supportive Care in Cancer; NCCN, National Comprehensive Cancer Network; NK₁, neurokinin-1; RA, receptor antagonist; SmPC, Summary of Product Characteristics.

References: **1.** ENHERTU (trastuzumab deruxtecan). Summary of Product Characteristics; **2.** Herrstedt J, et al. ESMO Open. 2024;9:102195; **3.** NCCN Clinical Practice, Guidelines in Oncology (NCCN Guidelines[®]) for Antiemesis V1.2025; **4.** Shin J, et al. Poster P4-05-08 presented at the 2024 San Antonio Breast Cancer Symposium (SABCS).

Scan the QR code (if viewing hard copy) to access Prescribing Information and Adverse Event Reporting details

Click the link (if viewing digitally) to access Prescribing Information and Adverse Event Reporting details

[Link](#)

